Esperion Therapeutics, Inc. Form SC 13G February 07, 2014

#### **UNITED STATES**

# SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. \_\_\_)\*

Esperion Therapeutics, Inc. (Name of Issuer)

Common Stock, par value \$0.001 per share (Title of Class of Securities)

29664W-10-5 (CUSIP Number)

December 31, 2013 (Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed.

o Rule 13d-1(b) o Rule 13d-1(c) x Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 29664W-10-5		S	Page SCHEDULE 13G	e 2 of 12			
		E OF REPORTING PERSON OR IDENTIFICATION NO. OF ABOVE PERSON					
	Aisling	Capi	ital II, LP				
2	CHECK	TH	E APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) o (b) x			
3	SEC US	E O	NLY				
4	CITIZE	NSH	IIP OR PLACE OF ORGANIZATION				
	Delawar	e					
		5	SOLE VOTING POWER				
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING		6	2,125,831 SHARED VOTING POWER				
			0				
		7	SOLE DISPOSITIVE POWER				
PERS WI			2,125,831				
		8	SHARED DISPOSITIVE POWER				
			0				
9	AGGRE	EGA.	TE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERS	SON			
	2,125,83	31 (S	See Item 4)				
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		N o				
11	PERCE	NT C	OF CLASS REPRESENTED BY AMOUNT IN ROW (9)				
	13.8%						
12	TYPE C	TYPE OF REPORTING PERSON					
	PN						

CUSIP No. 29664W-10-5		S	Pag SCHEDULE 13G	ge 3 of 1	2
1			REPORTING PERSON OR TIFICATION NO. OF ABOVE PERSON		
	Aisling	Capi	tal Partners, LP		
2	CHECK	THI	E APPROPRIATE BOX IF A MEMBER OF A GROUP		(a) o (b) x
3	SEC US	E Ol	NLY		
4	CITIZE	NSH	IP OR PLACE OF ORGANIZATION		
	Delawar	e			
		5	SOLE VOTING POWER		
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON		6	2,125,831 SHARED VOTING POWER		
		7	0 SOLE DISPOSITIVE POWER		
WIT		0	2,125,831		
		8	SHARED DISPOSITIVE POWER		
			0		
9	AGGRE	EGA]	TE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PER	.SON	
			ee Item 4)		
10	CHECK SHARE		X IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAI	[ <b>N</b>	O
11	PERCE	NT C	OF CLASS REPRESENTED BY AMOUNT IN ROW (9)		
	13.8%				
12	TYPE C	F RI	EPORTING PERSON		
	PN				

CUSIP No. 29664W-10-5		S	Page 4 SCHEDULE 13G	4 of 12			
1			REPORTING PERSON OR TIFICATION NO. OF ABOVE PERSON				
	Aisling	Capi	ital Partners, LLC				
2	CHECK	TH	E APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) o (b) x			
3	SEC US	E O	NLY				
4	CITIZE	NSH	IIP OR PLACE OF ORGANIZATION				
	Delawar	æ					
		5	SOLE VOTING POWER				
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON		6	2,125,831 SHARED VOTING POWER				
		7	0 SOLE DISPOSITIVE POWER				
	TH		2,125,831				
		8	SHARED DISPOSITIVE POWER				
			0				
9	AGGRE	EGA'	TE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSO	ON			
	2,125,83	31 (S	See Item 4)				
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES			0			
11	PERCE	NT C	OF CLASS REPRESENTED BY AMOUNT IN ROW (9)				
	13.8%						
12	TYPE C	TYPE OF REPORTING PERSON					
	OO						

CUSIP No. 29664W-10-5		SCHEDULE 13G			2
1			REPORTING PERSON OR TIFICATION NO. OF ABOVE PERSON		
	Steve El	ms			
2	CHECK	THI	E APPROPRIATE BOX IF A MEMBER OF A GROUP		(a) o (b) x
3	SEC US	E Ol	NLY		
4	CITIZE	NSH	IP OR PLACE OF ORGANIZATION		
	United S	States	S		
		5	SOLE VOTING POWER		
NUMBER SHAI BENEFIC OWN BY EA REPOR PERS WIT	RES CIALLY IED ACH TING SON	6 7 8	0 SHARED VOTING POWER  2,125,831 SOLE DISPOSITIVE POWER  0 SHARED DISPOSITIVE POWER  2,125,831		
9	AGGRE	GA7	ΤΕ AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PE	RSON	
10		ВО	ee Item 4) X IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTA	IN	0
11	PERCE	NT C	OF CLASS REPRESENTED BY AMOUNT IN ROW (9)		
12	13.8% TYPE C	F RI	EPORTING PERSON		
	IN				

CUSIP No. 29664W-10-5		S	Page 6 SCHEDULE 13G	of 12			
1			REPORTING PERSON OR TIFICATION NO. OF ABOVE PERSON				
	Dennis l	Purce	ell				
2	CHECK	TH	E APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) (b) 2			
3	SEC US	E O	NLY				
4	CITIZE	NSH	IIP OR PLACE OF ORGANIZATION				
	United S	States	s				
		5	SOLE VOTING POWER				
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING		6	0 SHARED VOTING POWER				
			2,125,831				
		7	SOLE DISPOSITIVE POWER				
	RSON ITH		0				
***		8	SHARED DISPOSITIVE POWER				
			2,125,831				
9	AGGRE	EGA'	TE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSO	N			
	2,125,83	31 (S	See Item 4)				
10		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		0			
11	PERCE	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)					
	13.8%						
12	TYPE C	TYPE OF REPORTING PERSON					
	IN						

CUSIP No. 29664W-10-5		S	SCHEDULE 13G	age 7 of 12			
		ME OF REPORTING PERSON OR S. IDENTIFICATION NO. OF ABOVE PERSON					
	Andrew	Schi	iff				
2	CHECK	TH	E APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) (b) 2			
3	SEC US	E O	NLY				
4	CITIZE	NSH	IIP OR PLACE OF ORGANIZATION				
	United S	States	s				
		5	SOLE VOTING POWER				
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING		6	0 SHARED VOTING POWER				
			2,125,831				
		7	SOLE DISPOSITIVE POWER				
	SON TH		0				
		8	SHARED DISPOSITIVE POWER				
			2,125,831				
9	AGGRE	EGA.	TE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PE	RSON			
	2,125,83	31 (S	See Item 4)				
10	CHECK SHARE		X IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTA	AIN o			
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)						
	13.8%						
12	TYPE C	)FR	EPORTING PERSON				
	IN						

CUSIP No. Page 8 of 12

29664W-10-5 SCHEDULE 13G

ITEM(a) Name of Issuer:

Esperion Therapeutics, Inc. (the "Issuer")

(b) Address of Issuer's Principal Executive Offices:

46701 Commerce Center Drive, Plymouth, MI 48170

ITEM(a) Name of Person Filing: 2.

This Schedule 13G (this "Statement") is being filed by the following persons (collectively, the "Reporting Persons"):

(i) Aisling Capital II, LP, a Delaware limited partnership ("Aisling");

(ii) Aisling Capital Partners, LP, a Delaware limited partnership ("Aisling Partners" and a general partner of

Aisling);

(iii) Aisling Capital Partners LLC, a Delaware limited liability company ("Aisling Partners GP" and a general partner of Aisling Partners);

Mr. Steve Elms ("Mr. Elms" and a managing member of

Aisling Partners GP);
(v) Mr. Dennis Purcell ("Mr. Purcell" and a managing

member of Aisling Partners GP); and

(vi) Mr. Andrew Schiff ("Mr. Schiff" and a managing member of Aisling Partners GP).

(b) Address of Principal Business Office, or if None, Residence:

(iv)

The address of the principal business offices of each of the Reporting Persons is 888 Seventh Avenue, 30th Floor, New York, New York 10106.

- (c) Citizenship:
  - (i) Aisling a Delaware limited partnership
  - (ii) Aisling Partners a Delaware limited partnership
  - (iii) Aisling Partners GP a Delaware limited liability company
  - (iv) Mr. Elms United States
  - (v) Mr. Purcell United States
  - (vi) Mr. Schiff United States

# Edgar Filing: Esperion Therapeutics, Inc. - Form SC 13G

	(d)	Title of Class of Securities:			
		Common Stock, par value \$0.001 per share (the "Common Stock").			
	(e)	CUSIP Number:			
		29664W-10-5			
ITEN 3.	MIF THIS STATEMENT IS I WHETHER THE PERSON	FILED PURSUANT TO §240.13D-1(B) OR 240.13D-2(B) OR (C), CHECK FILING IS A:			
	(a)	[] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o)			
	(b)	[] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c)			
	(c)	[] Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c)			
	(d)	[] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8)			
	(e)	[] An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E)			
	(f)	[] An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);			

CUSIP No. 29664W-10-5	SCHEDUI	Page 9 of 12 LE 13G		
	(g)	[] A Parent holding cor \$240.13d-1(b)(1)(ii)(G);	mpany or control person in accordance with	
	(h)		ns as defined in Section 3(b) of the Federal Deposit 1813)	
	(i)	[_] A church plan that is	s excluded from the definition of an investment c)(14) of the Investment Company Act of 1940 (15	
	(j) (k)	[] A non-U.S. institution	on in accordance with §240.13d-1(b)(1)(ii)(J); e with §240.13d-1(b)(1)(ii)(J).	
ITEM 4.	OWNERSHIP			
	(a)	Amount beneficially owner	ed:	
		of 2,125,831 shares of Co Common Stock and (ii) a	sons may be deemed to beneficially own an aggregate mmon Stock, consisting of (i) 2,054,594 shares of warrant to purchase 71,237 shares of Common Stock t an exercise price calculated in accordance with the	
	(b)	Percent of class:		
			made in accordance with Rule 13d-3(d), each of the deemed to beneficially own approximately 13.8% of Stock.	
		presented in this Statemer outstanding number of sha	thip of the Common Stock by Reporting Persons at is based on 15,357,413 shares which is the total ares of the Common Stock reported in the Issuer's 10-Q filed with the Securities Exchange Commission by 2013.	
	(c)	Number of shares as to wh	nich such person has:	
		(i), (iii)	Sole power to vote or to direct the vote	
			Each of Aisling, Aisling Partners and Aisling Partners GP may be deemed to have sole power to direct the voting and disposition of the 2,125,831 shares of Common Stock beneficially owned by Aisling.	
		(ii), (iv)	Shared power to vote or to direct the vote	

## Edgar Filing: Esperion Therapeutics, Inc. - Form SC 13G

By virtue of the relationships between and among the Reporting Persons as described in Item 2, each of Mr. Elms, Mr. Purcell and Mr. Schiff may be deemed to share the power to direct the voting and the disposition of the 2,125,831 shares of Common Stock beneficially owned by Aisling.

## ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

Not Applicable.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o .

#### ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

The partners of Aisling have the right to participate in the receipt of dividends from, or proceeds from the sale of, the Shares held for the account of Aisling in accordance with their ownership interests in Aisling.

# Edgar Filing: Esperion Therapeutics, Inc. - Form SC 13G

CUSIP No. Page 10 of 12

29664W-10-5 SCHEDULE 13G

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH

ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING

COMPANY.

Not Applicable.

ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

Not Applicable.

ITEM 9. NOTICE OF DISSOLUTION OF GROUP

Not Applicable.

ITEM 10. CERTIFICATIONS.

Not Applicable.

CUSIP No. Page 11 of 12

29664W-10-5 SCHEDULE 13G

#### **SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 7, 2014

AISLING CAPITAL II, LP

By: Aisling Capital Partners, LP,

As its General Partner

By: Aisling Capital Partners, LLC,

As its General Partner

By: /s/ Lloyd Appel

Name: Lloyd Appel

Title: Chief Financial Officer

AISLING CAPITAL PARTNERS, LP By: Aisling Capital Partners, LLC,

As its General Partner

By: /s/ Lloyd Appel

Name: Lloyd Appel

Title: Chief Financial Officer

AISLING CAPITAL PARTNERS, LLC

By: /s/ Lloyd Appel

Name: Lloyd Appel

Title: Chief Financial Officer

STEVE ELMS

By: /s/ Steve Elms

CUSIP No. 29664W-10-5	SCHEDULE 13G		Page 12 of 12		
		DENNIS P	URCELL		
		Ву:	/s/ Dennis Purcell		
		ANDREW	SCHIFF		
		Ву:	/s/ Andrew Schiff		

# EXHIBIT INDEX

Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as Exhibit 1.

Exhibit 1.